

Prostate-specific antigen screening from Urology Associates

Dear Provider,

One in seven men will be diagnosed with prostate cancer. In fact, prostate cancer is the **third leading cause** of cancer death in men. Unfortunately, the prostate cancer screening story over the past decade has been one of controversy and confusion. Diagnostic techniques have evolved.

Using [Select MDx](#) and other tools, our emphasis is to stratify patients' risks to harmful prostate cancers and only biopsy those at greatest risk. This testing reduced the rate of biopsies by approximately 30%.

Urology Associates is using the most sophisticated techniques available--- not only before any prostate biopsy, but afterward to give patients the most individualized care possible. With advanced genomic testing such as [Oncotype DX](#), [Prolaris](#), [Confirm DX](#) and [Decipher](#), we can identify who has a favorable "genomic fingerprint" and can safely avoid additional treatment. In fact, 30% of our patients diagnosed with prostate cancer today can be safely observed without aggressive treatment. We also can determine those who may benefit from more aggressive therapeutic options.

According to the [American Urological Association](#), African American males and those with a family history should start the conversation regarding screening at age 40. If you haven't already, start the conversation and give your patients the best by referring them to us for prevention, screening, and treatment for prostate cancer.

Call **262-446-3593** to learn more about our PSA screening.

We look forward to hearing from you!